-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Climb Bio, Maintains $32 Price Target

Benzinga·10/27/2026 09:52:35
Listen to the news
BTIG analyst Julian Harrison reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $32 price target.